Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating activities:
Net loss	$ (34,681)	$ (26,525)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,491	1,126
Net amortization of premiums on marketable securities	296	418
Amortization of debt discount	243	262
Amortization of loan fees	7	73
Warrant expense related to vesting of ADM Warrant	191	0
Stock-based compensation expense	6,609	4,005
Loss from equity method investment	3,834	959
Revaluation of warrant liability	(688)	(54)
Revaluation of derivative liability	(2,018)	737
Changes in operating assets and liabilities:
Accounts receivable	(447)	(4,040)
Unbilled revenue	(605)	874
Inventories	(1,076)	222
Prepaid expenses and other current assets	(158)	485
Other assets	1,460	0
Accounts payable	1,902	(2,129)
Accrued liabilities	(5,595)	2,724
Deferred revenue	662	3,142
Other current and long-term liabilities	(67)	(499)
Net cash used in operating activities	(28,640)	(18,220)
Investing activities:
Purchases of property, plant and equipment	(2,676)	(1,189)
Purchases of marketable securities	(5,705)	(83,581)
Maturities of marketable securities	32,625	17,618
Proceeds from sales of marketable securities	2,748	0
Capital contribution in unconsolidated joint venture	(8,050)	(5,500)
Capitalized interest related to unconsolidated joint venture	(350)	0
Net cash provided by (used in) investing activities	18,592	(72,652)
Financing activities:
Repayments under loan agreements	(16)	(14,872)
Proceeds from the issuance of senior subordinated convertible notes, net of debt discount	0	119,750
Proceeds from the issuance of common stock	4,914	260
Proceeds from issuance of common stock, pursuant to ESPP	709	516
Early exercise of stock options subject to repurchase	(4)	(8)
Proceeds from borrowings under loan agreements	0	10,369
Payment for loan costs and fees	0	(500)
Cash settlement of vested restricted stock units	(68)	0
Net cash provided by financing activities	5,535	115,515
Effect of exchange rate changes on cash and cash equivalents	42	(21)
Net (decrease) increase of cash and cash equivalents	(4,471)	24,622
Cash and cash equivalents - beginning of period	54,977
Cash and cash equivalents - end of period	50,506
Supplemental disclosures of cash flow information:
Interest paid in cash, net of capitalized interest	2,194	183
Income taxes paid in cash	0	0
Supplemental disclosure of noncash investing and financing activities:
Capital assets in accounts payable and accrued liabilities	1,225	502
Accrued offering costs	210	0
Debt issue costs in accounts payable and accrued liabilities	417	118
Change in unrealized (loss) gain on marketable securities	(12)	(69)
Foreign currency translation adjustment related to unconsolidated joint venture	1,094	0
Common stock issued in lieu of cash bonus	0	121
Common stock issued in connection with use and operation of third party manufacturing facility	0	2,655
Conversion of Senior Convertible Notes to common stock	2,461	0
Early conversion payment on Senior Convertible Notes settled in common stock	$ 217	$ 0